After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

GSK PLC GSK shares rallied 1.20% to £15.12 Thursday, on what proved to be an all-around favorable trading session for the ...

UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

GSK PLC closed 11.54% below its 52-week high of £16.79, which the company reached on September 9th.

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.